Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study

被引:4
作者
Bokemeyer, Bernd [1 ,2 ,6 ]
Plachta-Danielzik, Sandra [3 ]
di Giuseppe, Romina [3 ]
Helwig, Ulf
Teich, Niels
Schmidt, Carsten [4 ,5 ]
Hartmann, Petra
Sobotzki, Christina [3 ]
Schreiber, Stefan [2 ]
机构
[1] Interdisciplinary Crohn Colitis Ctr Minden, Minden, Germany
[2] Univ Med Ctr Schleswig Holstein, Dept Internal Med Gastroenterol Hepatol Pulmonol I, Campus Kiel,Arnold Heller Str 3, Kiel, Germany
[3] Competence Network IBD, Kiel, Germany
[4] Hosp Fulda, Med Clin 2, Fulda, Germany
[5] Friedrich Schiller Univ, Med Fac, Jena, Germany
[6] Univ Kiel, Interdisciplinary Crohn Colitis Ctr Minden, Dept Med 1, UKSH, Marchenweg 17, D-32439 Kiel, Germany
关键词
INFLAMMATORY-BOWEL-DISEASE; CLINICAL-COURSE; POPULATION; BEHAVIOR; PHENOTYPE; PROGRESSION; LOCATION; FISTULAS; COHORT; ICURE;
D O I
10.1111/apt.17512
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Under the assumption of irreversibility, the Montreal classification provides a unidirectional assessment of the complications and behaviour of Crohn's disease (CD) that does not allow for downstaging. We examined the use of a bidirectional Montreal classification system that can capture disease regression. Design: From the BioCrohn Registry, an inception cohort of patients with CD for <= 12 months duration was defined and followed up for 5-years. Cumulative probabilities for developing complications were estimated using the Kaplan-Meier method. Potential associations of explanatory variables with disease progression were estimated with Cox regression. Results: Among 393 incident CD patients (of whom 255 completed the entire follow-up), the 5-year cumulative probability of developing complications was 41.5% (15.6% and 25.9% for stricturing and penetrating complications respectively). Perianal disease (hazard ratio [95% confidence interval]: 8.45 [4.74-15.07]) and surgical resection of the intestine (2.71 [1.50-4.92]) in the very early phase of the disease were associated with a higher risk of developing a penetrating complication within the 5-year follow-up. The use of a bidirectional Montreal classification system which can account for disease regression demonstrated that 90% of patients exhibited inflammatory disease behaviour at 5 years, in contrast to 58%, if the hierarchical, unidirectional Montreal classification system was used. Conclusion: An additional bidirectional disease behaviour assessment capturing reversed or fully controlled complications may provide a more realistic appraisal of the complexity and unmet needs of patients treated with advanced therapies.
引用
收藏
页码:35 / 47
页数:13
相关论文
共 40 条
[1]   Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification [J].
Aldhous, Marian C. ;
Drummond, Hazel E. ;
Anderson, Niall ;
Smith, Linda A. ;
Arnott, Ian D. R. ;
Satsangi, Jack .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (03) :577-588
[2]   Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review [J].
Armijo-Olivo, Susan ;
Warren, Sharon ;
Magee, David .
PHYSICAL THERAPY REVIEWS, 2009, 14 (01) :36-49
[3]   Predictors of Crohn's disease [J].
Beaugerie, L ;
Seksik, P ;
Nion-Larmurier, I ;
Gendre, JP ;
Cosnes, J .
GASTROENTEROLOGY, 2006, 130 (03) :650-656
[4]   Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease [J].
Bislenghi, G. ;
Wolthuis, A. ;
Van Assche, G. ;
Vermeire, S. ;
Ferrante, M. ;
D'Hoore, A. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (07) :607-616
[5]   Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting [J].
Bokemeyer, B. ;
Ghiani, M. ;
Fuchs, A. ;
Deiters, B. ;
Hardtstock, F. ;
Brandes, A. ;
Knop, J. ;
Orzechowski, H. D. ;
Wilke, T. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (08) :1587-1598
[6]  
Bokemeyer B., 2011, J CROHNS COLITIS, P6
[7]  
Bokemeyer B., 2013, J CROHNS COLITIS, V7, pS2
[8]   Addressing unmet needs in inflamatory bowel disease [J].
Bokemeyer, Bernd .
DRUG DISCOVERY TODAY, 2015, 20 (09) :1037-1039
[9]   Real-world biologic treatment and associated cost in patients with inflammatory bowel disease [J].
Brandes, Alina ;
Groth, Antje ;
Gottschalk, Fraence ;
Wilke, Thomas ;
Ratsch, Boris A. ;
Orzechowski, Hans-Dieter ;
Fuchs, Andreas ;
Deiters, Barthold ;
Bokemeyer, Bernd .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (07) :843-851
[10]   Changes in Crohn's disease phenotype over time in the chinese population: Validation of the Montreal classification system [J].
Chow, Dorothy K. L. ;
Leong, Rupert W. L. ;
Lai, Larry H. ;
Wong, Grace L. H. ;
Leung, Wai-Keung ;
Chan, Francis K. L. ;
Sung, Joseph J. Y. .
INFLAMMATORY BOWEL DISEASES, 2008, 14 (04) :536-541